

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

## Product Datasheet

### Galunisertib, CAS [[700874-72-2]] FBM-10-4110

|                            |                                                         |
|----------------------------|---------------------------------------------------------|
| Article Name               | Galunisertib, CAS [[700874-72-2]]                       |
| Biozol Catalog Number      | FBM-10-4110                                             |
| Supplier Catalog Number    | 10-4110                                                 |
| Alternative Catalog Number | FBM-10-4110-5MG,FBM-10-4110-25MG                        |
| Manufacturer               | Focus Biomolecules                                      |
| Category                   | Biochemikalien                                          |
| Product Description        | TGFβ receptor 1 inhibitor / Cancer immunotherapeutic... |
| Molecular Weight           | 369.43                                                  |
| Purity                     | 98%, NMR (Conforms)                                     |
| Form                       | White solid                                             |
| CAS Number                 | [700874-72-2]                                           |
| Formula                    | C22H19N5O                                               |

Application Notes

Galunisertib is a TGF- $\beta$  kinase (ALK5) antagonist.<sup>1</sup> It stimulated hematopoiesis from primary myelodysplastic syndrome bone marrow specimens via downregulation of SMAD2 phosphorylation.<sup>2</sup> It has been in clinical trials for treatment of various cancers.<sup>3-5</sup> Galunisertib has more recently been used to enhance the anti-neuroblastoma activity of anti-GD2 antibody Dinutuximab with natural killer cells<sup>6</sup> and preserved the function of in vitro expanded natural killer cells in AML and colon cancer models<sup>7</sup>. Galunisertib reversed TGF and regulatory T cell mediated suppression of human T cell proliferation. In combination with PD-L1 blockade, it resulted in improved tumor growth inhibition and complete regressions in colon carcinoma models.<sup>8</sup>